PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of bmccancBioMed Centralsearchsubmit a manuscriptregisterthis articleBMC Cancer
 
BMC Cancer. 2012; 12: 166.
Published online May 4, 2012. doi:  10.1186/1471-2407-12-166
PMCID: PMC3469344
Novel synergistic antitumor effects of rapamycin with bortezomib on hepatocellular carcinoma cells and orthotopic tumor model
Cun Wang,#1,2 Dongmei Gao,#1 Kun Guo,1 Xiaonan Kang,2 Kai Jiang,2 Chun Sun,1,2 Yan Li,1 Lu Sun,2 Hong Shu,1 Guangzhi Jin,1,2 Haiyan Sun,1,2 Weizhong Wu,1 and Yinkun Liucorresponding author1,2
1Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Shanghai, 200032, China
2Institutes of Biomedical Sciences, Fudan University, Shanghai, 200032, China
corresponding authorCorresponding author.
#Contributed equally.
Cun Wang: wangcun830724/at/hotmail.com; Dongmei Gao: gao.dongmei/at/zs-hospital.sh.cn; Kun Guo: jacky.guo.joan/at/gmail.com; Xiaonan Kang: xnkang7/at/163.com; Kai Jiang: jk927/at/163.com; Chun Sun: bacchicsc/at/hotmail.com; Yan Li: liyansmu/at/yahoo.com.cn; Lu Sun: sunlu36/at/hotmail.com; Hong Shu: shuhong81530/at/hotmail.com; Guangzhi Jin: jgzhi/at/hotmail.com; Haiyan Sun: shyfd_hi/at/163.com; Weizhong Wu: wu.weizhong/at/zs-hospital.sh.cn; Yinkun Liu: liu.yinkun/at/zs-hospital.sh.cn
Received February 8, 2012; Accepted May 4, 2012.
Abstract
Background
Despite recent advances in the treatment of hepatocellular carcinoma (HCC), the chemotherapy efficacy against HCC is still unsatisfactory. The mammalian target of rapamycin (mTOR) has been emerged as an important cancer therapeutic target. However, HCC cells often resistant to rapamycin because of the paradoxical activation of Akt by rapamycin. In this study, we investigated whether bortezomib could enhance the antitumor effects of rapamycin.
Methods
The effects of rapamycin and bortezomib on HCC proliferation, apoptosis, migration, and invasiveness in vitro were assessed by CCK-8 analysis, flow cytometry, Hoechst 33342 staining and transwell assays, respectively. Total and phosphorylated protein levels of Akt were detected by Western blotting. The effects of rapamycin and/or bortezomib on the mRNA expression levels of p53, p27, p21 and Bcl-2 family in HCCLM3 cells were evaluated by RT-PCR. The roles of rapamycin and bortezomib on HCC growth and metastasis in xenograft models were evaluated by tumor volumes and fluorescent signals. The effects of rapamycin and bortezomib on cell proliferation and apoptosis in vivo were test by PCNA and TUNEL staining.
Results
Bortezomib synergized with rapamycin to reduce cell growth, induce apoptosis, and inhibit cell mobility in vitro. Further mechanistic studies showed that bortezomib inhibited rapamycin-induced phosphorylated Akt, which in turn enhanced apoptosis of HCC cell lines. The alteration of the mRNA expression of cell cycle inhibitors p53, p27, p21 and apoptosis associated genes Bcl-2, Bax were also involved in the synergistic antitumor effects of rapamycin and bortezomib. P53 inhibitor PFT-α significantly attenuate the effect of rapamycin and bortezomib on cell apoptosis, which indicated that the pro-apoptotic effect of rapamycin and bortezomib may be p53-dependent. Treatment of HCCLM3-R bearing nude mice with rapamycin and bortezomib significantly enhanced tumor growth inhibition (72.4%), comparing with either rapamycin- (54.7%) or bortezomib-treated mice (22.4%). In addition, the lung metastasis was significantly suppressed in mice received the combination treatment (16.6%). The combination treatment of rapamycin and bortezomib significantly inhibited tumor cell proliferation and tumor angiogenesis in vivo.
Conclusion
The combination of rapamycin with bortezomib could be a novel and promising therapeutic approach to the treatment of HCC.
Keywords: Rapamycin, Bortezomib, mTOR, Akt, Hepatocellular carcinoma
Articles from BMC Cancer are provided here courtesy of
BioMed Central